News

Company News & Events

Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry

19 February 2018

MADRID, SPAIN and CAMBRIDGE MA.

• José Carlos Gutiérrez-Ramos, President and CEO of Synlogic joins as Independent Director

• NAJETI family fund steps down

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced by means of a “relevant fact” to the CNMV changes on its corporate governing bodies.

 

Click here to see the full Press Release

 

Posted In: 
Investors
News

Share this story